<DOC>
	<DOC>NCT01337011</DOC>
	<brief_summary>This is a pilot study comparing the effect of intra-coronary versus intramyocardial application of enriched CD133pos autologous bone marrow derived stem cells for improving left ventricular function in chronic ischemic cardiomyopathy.</brief_summary>
	<brief_title>Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Patients 18 to 80 years old Of female and male gender Patient has reduced ejection fraction as evaluated by routine clinical angiogram, echocardiography or MRI (≤45%) due to ischemic heart disease symptomatic heart failure NYHA ≥ II on optimal therapy coronary artery in the target region that can be used for cell infusion Patient has been informed of the nature of the clinical trial and agrees to its provision and has provided written informed consent planned or performed CABG surgery or PCI within 4 weeks of study entry recent myocardial infarction (&lt; 6 months) TIMI flow &lt; II in the coronary artery selected for infusion cardiogenic shock requiring mechanical ventilation or intraaortic balloon pump progressive tumor disease primary disease of bone marrow including malfunction of components of the coagulation system women of childbearing age premenopausal LV wall thickness &lt; 5mm at planned site of injection ventricular wall thrombus severe aortic valvular heart disease severe atrial or ventricular tachycardia unresponsive to intravenous or oral drug therapy aneurysm of the anterior wall history of stroke know diseases of the liver resulting in reduced plasmatic coagulation with spontaneous INR &gt;2 patients with chronic infectious diseases (HBV, HCV, HIV, seropositivity for Treponema pallidum) patients taking part or have taken part in other clinical trials within the past 3 months patients unable to provide informed consent any other medical condition that the enrolling physician deems significant in representing a potential hazard for the patient when participating in this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Chronic Ischemic Cardiomyopathy</keyword>
</DOC>